



CME SATELLITE SYMPOSIUM

Add to your calendar: tinyurl.com/y6dnyrnn

IGF-1R: Pathophysiology in THYROID EYE DISEASE and Rationale for Its Blockade

Sunday, 10 September

11:10 - 12:10

Room 208

University of Milan
Via Festa del Perdono 7
City Center
Milan, Italy

This continuing education
activity is provided by



This activity is supported by an educational
grant from Horizon Therapeutics Ireland DAC.

Held in conjunction with the 45th Annual Meeting of the European Thyroid Association.



ACTIVITY CHAIR

GEORGE J. KAHALY, MD, PHD

Professor of Medicine and
Endocrinology/Metabolism
Department of Medicine I
Johannes Gutenberg University Medical Center
Mainz, Germany



ANDREA LORA KOSSLER, MD, FACS

Director, Oculofacial Plastic and Orbital Surgery
Associate Professor of Ophthalmology
Byers Eye Institute at Stanford University
School of Medicine
Palo Alto, CA, United States



SARA TULLIS WESTER, MD, FACS

Professor of Clinical Ophthalmology
Oculofacial Plastic and Reconstructive Surgery
Orbital Surgery and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL, United States

JOIN US for a CME satellite symposium on thyroid eye disease (TED). TED is an autoimmune condition caused by stimulation of insulin-like growth factor 1 (IGF-1) and thyroid-stimulating hormone receptors in the orbital fibroblasts. Traditional therapies do not provide a cure or modify disease course and often have long-term adverse events, but the therapeutic landscape is changing. **Drs. George J. Kahaly, Sara Tullis Wester, and Andrea Lora Kossler** will review the role of IGF-1 receptors in the pathogenesis of TED, multidisciplinary teams in diagnosis and treatment, and the safety and efficacy of conventional, new, and emerging therapies.

AGENDA

11:10 Introduction

George J. Kahaly, MD, PhD

11:15 Basic Findings and Rationale for Inhibiting the IGF-1R

George J. Kahaly, MD, PhD

11:27 US Real-World Case Discussions: Treating Thyroid Eye Disease

Sara Tullis Wester, MD

11:42 Monitoring and Managing Adverse Events of Targeted IGF-1R Therapy: What We Know Now

Andrea Lora Kossler, MD

11:57 Posttest and Question & Answer

12:10 Conclusion

LEARNING OBJECTIVES

Upon successful completion of the activity, participants should be better able to:

- Review the pathogenesis of thyroid eye disease and the role of insulin-like growth factor 1 receptor (IGF-1R).
- Assess multidisciplinary practices and procedures that can improve the early diagnosis and treatment of TED.
- Compare the efficacy and safety of conventional, new, and emerging therapies for the treatment of TED.

TARGET AUDIENCE

The intended audience for this activity is endocrinologists and other healthcare professionals involved in the management of patients with TED.



Add to your calendar:
tinyurl.com/y6dnyrnn



In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Vindico Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is designed for *AMA PRA Category 1 Credit(s)*[™] for US physicians only. All non-US physicians should contact their respective Boards for accreditation/credit status.